Law Firm Investigates Select Medical Board Over $16.50 Take-Private Deal Fairness
SEM sits 42% above its 52-week low of $11.65.
Summary
A securities law firm has launched an investigation into Select Medical's board of directors for potential breaches of fiduciary duties regarding the pending $16.50 per share take-private acquisition. This follows numerous SEC filings since April detailing the definitive merger agreement, with the shareholder vote now set for June 26. The investigation focuses on the fairness of the offer price, particularly as insiders are permitted to roll over their equity while public shareholders are not. This legal challenge introduces uncertainty into the deal's completion and could lead to demands for a higher offer or litigation, impacting the stock price which is currently trading just above the offer. Investors should watch the upcoming shareholder vote on June 26, 2026, and any further legal developments.
At the time of this announcement, SEM was trading at $16.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $11.65 to $16.99. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.